1 / 2

Impact of Atorvastatin on eGFR in CKD Patients: A Study by Amarenco et al.

This study by Amarenco et al. explores the effects of Atorvastatin compared to Placebo on eGFR changes in participants with and without CKD over a 36-month period. Least squares mean changes in eGFR (ml/min/1.73m2) were assessed at baseline, 12, 24, and 36 months. The findings provide insights into the potential benefits of Atorvastatin in renal function management.

zoey
Télécharger la présentation

Impact of Atorvastatin on eGFR in CKD Patients: A Study by Amarenco et al.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Change in eGFR with atorvastatin or placebo in participants with CKD 6 Atorvastatin Placebo 4 Least squares mean change in eGFR (mlL/min/1.73m2 2 0 -2 baseline 48 60 12 24 36 Study visit (months) Amarenco et al., Stroke 2014

  2. Change in eGFR with atorvastatin or placebo in participants without CKD 6 Atorvastatin Placebo 4 Least squares mean change in eGFR (mlL/min/1.73m2 2 0 -2 baseline 48 60 12 24 36 Study visit (months)

More Related